Neoadjuvant nivolumab combination treatment in resectable non-small cell lung cancer patients: Defining optimal combinations and determinants of immunological response (NEOpredict-Lung)
This research study, called NEOpredict-Lung, is exploring new ways to treat early-stage non-small cell lung cancer using a combination of medicines given through a drip before surgery. The main goal is to see how many patients can successfully have their lung cancer removed by surgery within 43 days of starting these new treatments. We're also looking at how well the tumours shrink, if all the cancer can be removed, and how long people stay healthy after treatment. The study aims to find the best combinations of these drugs and understand how they help the body's immune system fight the cancer. This is a Phase II study, meaning we're exploring the effectiveness and safety of these new approaches.
At a glance
What is this study about?
This study, called NEOpredict-Lung, is designed for people with early-stage non-small cell lung cancer. This type of lung cancer is often found early enough that surgery can be a very effective treatment. We're looking at giving a combination of new medicines, Relatlimab and OPDIVO (which contains nivolumab), through a drip before the surgery. The idea behind giving medicine before surgery, called neoadjuvant treatment, is to try and shrink the tumour first. This might make the surgery easier and more successful, and potentially improve the chances of a full recovery.
The main thing we want to find out is how many patients who receive these treatments can then go on to have their lung cancer successfully removed by surgery within about six weeks of starting the treatment. We're also tracking other important things like how much the tumour shrinks, if the doctors can remove all the cancer, how people feel, and how long they stay well after treatment. We'll also be looking closely at how these medicines affect the body's immune system to understand how they help fight the cancer.
This is a Phase II study, which means it's an important step in researching new treatments. It's about exploring if these specific combinations of drugs are effective and safe for people with certain stages of lung cancer. The information we gather will help doctors understand better ways to treat this type of cancer in the future and personalise treatment plans for patients.
Key takeaways
- Exploring new drug combinations for early lung cancer.
- Medicines are given before surgery to shrink tumours.
- Aims to improve surgical outcomes and patient recovery.
- Involves immunotherapy drugs to boost the body's defences.
- This is a Phase II study, exploring effectiveness and safety.
Who may be eligible?
To be considered for this study, you would need to be an adult, aged 18 years or older.
This study is for people who have early-stage non-small cell lung cancer. Specifically, it's for those whose cancer doctors have identified as clinical stages IB, II, or certain cases of stage IIIA.
Both men and women can take part in this research. Your cancer care team will need to check other detailed criteria to make sure this study is right for you and safe for your specific health situation.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Do you have non-small cell lung cancer?
- Has your doctor told you your cancer is clinical stage IB, II, or selected stage IIIA?
- Are you able to undergo surgery for your lung cancer?
What does participation involve?
If you decide to join this study, you would receive the study medications (Relatlimab and OPDIVO) through a drip. These treatments would be given before your planned surgery. The main goal is to see if surgery can happen within 43 days of you starting the study treatment. Throughout the study, you'll have regular hospital visits for medical checks, blood tests, and scans to see how you're responding to the treatment and to monitor your health. After your surgery, there will be follow-up appointments over a period of time to check on your recovery and overall health. The specific number of visits and tests will be explained in detail by the study team, but generally, studies like this involve more frequent visits than standard care.
Potential risks and benefits
Locations (3)
- —UnverifiedNetherlands
- —UnverifiedGermany
- —UnverifiedBelgium
Common questions
What is 'non-small cell lung cancer'?
It's the most common type of lung cancer, and this study focuses on earlier stages where surgery is a main treatment option.
What does 'neoadjuvant treatment' mean?
It means receiving medicine, like the drugs in this study, before your main surgery to help shrink the tumour.
What are Relatlimab and OPDIVO?
These are types of immunotherapy drugs that help your body's own immune system fight cancer.
How long will I be on the study drugs before surgery?
The study aims for surgery to happen within 43 days (about six weeks) of starting the treatment.
Will I still have surgery if I join this study?
Yes, the main goal of this study is to see how successful surgery is after receiving these new treatments.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.